Janssen Korea targets 210 billion won sales

Janssen Korea has set a goal of 210 billion won in sales this year, with its ambitious plan to launch four new drugs, such as Intelence, Jurnista, Invega and Yondelis.

- Intelence (etravirine) is a drug used for the treatment of HIV. Intelence is a non-nucleoside reverse transcriptase inhibitor (NNRTIs). Unlike the currently available agents in the class, resistance to other NNRTIs does not ...